QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Senate backs prostate cancer awareness month—a public health win

S.Res. 436 — A resolution expressing support for the designation of September 2025 as "National Prostate Cancer Awareness Month". · Filed by Mike Crapo (R-ID) · 3 cosponsors · Introduced Oct 6, 2025 · Passed chamber

95%
Transparency
Typical bill: 82%
5/100
Hidden-provision risk
Typical bill: 15/100
Public Health Awareness Resolution

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This is a Senate resolution expressing support for designating September 2025 as 'National Prostate Cancer Awareness Month.' It documents the scale of prostate cancer in the U.S. (3.3 million men living with it, 1 in 8 lifetime diagnosis risk), notes federal research funding ($7.2 billion to the National Cancer Institute, $75 million to the Defense Department's Prostate Cancer Research Program), and calls on Americans, health organizations, and government to raise awareness about screening and treatment.

Why we flagged it

This is a non-binding commemorative resolution that designates a month for public awareness of a significant health condition. It contains no legislative mechanism, appropriations, or regulatory change—only a call for awareness and continued research support.

What the text implies

  • Implicit endorsement of prostate cancer screening may influence clinical practice and patient demand, potentially increasing screening volume and associated healthcare costs (both diagnostic and treatment-related).
  • Resolution cites specific federal funding levels ($7.2B to NCI, $75M to DoD program), which may signal congressional intent to maintain or increase these appropriations in future budget cycles.

The full analysis lists 3 implications of this text.

Who stands to gain

pharmaceutical companies (cancer treatment drugs); medical device manufacturers (diagnostic and treatment equipment); healthcare providers and hospital systems (screening and treatment services)

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record